Financial Performance - The company's operating revenue for Q3 2024 was ¥50,139,668.31, a decrease of 33.91% compared to the same period last year[2] - The net profit attributable to shareholders was -¥13,802,326.80, representing a decline of 379.15% year-over-year[2] - The basic earnings per share were -¥0.17, down 383.33% from the previous year[2] - Total operating revenue for Q3 2024 was CNY 200,520,158.82, a decrease of 18.6% compared to CNY 246,256,774.84 in Q3 2023[12] - The net profit for Q3 2024 was 375,516.07, a significant decrease compared to the net profit of 2,766,997.50 in the same period last year, indicating a decline in profitability[13] - The total comprehensive income attributable to the parent company was -17,078,738.20, a decrease from 27,212,187.03 in the previous year, highlighting a challenging financial environment[14] - The company experienced a net loss of -26,558,336.82 from continuing operations, compared to a profit of 17,653,964.14 in the previous year, indicating operational challenges[14] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,070,004,588.91, a slight decrease of 0.21% from the end of the previous year[2] - The equity attributable to shareholders decreased by 6.23% to ¥723,970,156.40 compared to the end of the previous year[2] - Total liabilities increased to CNY 303,857,171.27 from CNY 250,588,538.76, indicating a rise of 21.3%[12] - The company's equity attributable to shareholders decreased to CNY 723,970,156.40 from CNY 772,064,892.00, a decline of 6.2%[12] Cash Flow - Cash flow from operating activities showed a net outflow of -¥29,351,723.96, a decline of 221.46% year-over-year[2] - The company's cash and cash equivalents decreased from ¥405,270,705.96 at the beginning of the period to ¥255,400,920.06 at the end of the period[10] - The net cash flow from operating activities was -29,351,723.96 CNY, a decrease compared to 24,166,611.22 CNY in the previous year[16] - Cash inflow from operating activities totaled 242,072,654.06, down from 340,445,845.95 in the previous year, indicating reduced cash generation from operations[15] - The company reported a total cash outflow from operating activities of 271,424,378.02 CNY, compared to 316,279,234.73 CNY in the previous year[16] Inventory and Costs - The company reported a significant increase in inventory, which rose by 81.49% to ¥60,124,369.99 due to new business operations[5] - The company experienced a 65.49% rise in operating costs, totaling ¥118,802,890.86, attributed to changes in product structure[5] - Total operating costs for Q3 2024 were CNY 233,238,610.81, slightly down from CNY 239,577,465.50 in the same period last year[12] - Accounts receivable increased to CNY 95,560,728.16 from CNY 79,736,341.25, reflecting a growth of 19.5% year-over-year[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,225[6] - The largest shareholder, Tibet Jiakang Times Technology Development Co., Ltd., holds 58.35% of shares, totaling 46,677,966 shares[6] - The total number of shares with unlimited sale conditions held by the company’s repurchase account is 1,044,500 shares, representing 1.31% of total shares[8] - The total number of restricted shares held by major shareholders at the beginning of the period was 52,576,271 shares, which were all released by the end of the period[9] Expenses and Investments - Financial expenses increased by 120.23% to ¥692,422.29, primarily due to increased loans[5] - Research and development expenses increased to 17,986,703.87, up from 14,753,007.10 in the previous year, reflecting a focus on innovation[13] - The company reported a significant increase in financial expenses, with interest expenses rising to 4,272,293.15 from 2,324,663.31 in the previous year[13] - Investment income increased by 50.73% to ¥6,153,254.01, driven by higher returns from financial investments[5] - Cash inflow from investment activities totaled 648,374,958.69 CNY, significantly higher than 289,500,862.76 CNY in the same period last year[16] Other Information - The company has not disclosed any new product or technology developments in this report[8] - There are no significant changes in the top ten shareholders' participation in margin trading or securities lending activities[8] - The company has not reported any market expansion or acquisition strategies in this quarter[8] - The company did not undergo an audit for the third quarter report[17]
多瑞医药(301075) - 2024 Q3 - 季度财报